Evotec AG O.N. (EVTG)

Xetra
Currency in EUR
7.330
-0.182(-2.42%)
Closed·
EVTG Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 6 days
Fair Value
Day's Range
7.1847.532
52 wk Range
5.06010.660
Key Statistics
Edit
Bid/Ask
7.318 / 7.34
Prev. Close
7.512
Open
7.5
Day's Range
7.184-7.532
52 wk Range
5.06-10.66
Volume
1.31M
Average Volume (3m)
971.43K
1-Year Change
-21.95%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EVTG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.800
Upside
+60.98%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Evotec AG O.N. Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It also has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital, as well as a strategic research collaboration agreement with Bristol Myers Squibb to build a molecular glue based pipeline for unmet medical needs. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Employees
4740
Market
Germany

Compare EVTG to Peers and Sector

Metrics to compare
EVTG
Peers
Sector
Relationship
P/E Ratio
−6.6x15.4x−0.5x
PEG Ratio
0.050.020.00
Price/Book
1.4x2.1x2.6x
Price / LTM Sales
1.6x4.7x2.9x
Upside (Analyst Target)
50.1%814.1%56.4%
Fair Value Upside
Unlock14.1%9.3%Unlock

Analyst Ratings

4 Buy
3 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.800
(+60.98% Upside)

Earnings

Latest Release
Apr 17, 2025
EPS / Forecast
-0.23 / -0.0699
Revenue / Forecast
221.20M / 223.18M
EPS Revisions
Last 90 days

People Also Watch

28.020
IDR
+2.79%
36.570
BOSSn
+1.13%
52.88
R3NK
+2.78%
6.776
FRVIA
-1.25%
6.790
DEZG
+2.57%

FAQ

What Is the Evotec AG (EVTG) Stock Price Today?

The Evotec AG stock price today is 7.33

What Stock Exchange Does Evotec AG Trade On?

Evotec AG is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Evotec AG?

The stock symbol for Evotec AG is "EVTG."

What Is the Evotec AG Market Cap?

As of today, Evotec AG market cap is 1.30B.

What is Evotec AG Earnings Per Share?

The Evotec AG EPS is -1.11.

What Is the Next Evotec AG Earnings Date?

Evotec AG will release its next earnings report on May 06, 2025.

From a Technical Analysis Perspective, Is EVTG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.